A Study of LY3841136 in Overweight and Obese Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

96 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-03

Study Completion Date

2025-09-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

NCT06603571

Obesity Overweight

ACTIVE_NOT_RECRUITING PHASE2

A Study of LY3457263 in Obese Participants

NCT05582096

Overweight Obesity

COMPLETED PHASE1

A Study of LY3841136 in Japanese Participants With Obesity or Overweight

NCT06297616

Obesity Overweight

COMPLETED PHASE1

A Study of LY3841136 in Healthy and Overweight Participants

NCT05295940

Obesity Healthy

COMPLETED PHASE1

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

NCT06230523

Obesity Overweight and Obesity

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Overweight

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3841136 + Tirzepatide

LY3841136 administered subcutaneously (SC) in combination with tirzepatide given SC.

Group Type EXPERIMENTAL

Tirzepatide

Intervention Type DRUG

Administered SC.

LY3841136

Intervention Type DRUG

Administered SC.

Placebo + Tirzepatide

Placebo administered SC in combination with tirzepatide given SC.

Group Type PLACEBO_COMPARATOR

Tirzepatide

Intervention Type DRUG

Administered SC.

Placebo

Intervention Type DRUG

Administered SC.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tirzepatide

Administered SC.

Intervention Type DRUG

LY3841136

Administered SC.

Intervention Type DRUG

Placebo

Administered SC.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female participants who are overtly healthy as determined by medical evaluation
* Have a stable body weight and Body Mass Index in range of 27 to 45 kilogram per meter square (kg/m²).
* Have clinical laboratory test results within normal reference range
* Have venous access sufficient to allow for blood sampling
* Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures

Exclusion Criteria

* Have type 1 or type 2 diabetes mellitus
* Have an abnormal 12-lead electrocardiogram (ECG)
* Have a history or presence of psychiatric disorders
* Have abnormal blood pressure and pulse rate
* Are currently enrolled in another clinical study trial involving medical research or have participated within the last 30 days in a clinical study involving an investigational product.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No